Designing biologic selectivity for inflammatory bowel disease – role of vedolizumab

• Main Authors: Krupka N, Baumgart DC
• Format: Article
• Language: English
• Published: Dove Medical Press 2014-12-01
• Series: Drug Design, Development and Therapy
• Online Access: http://www.dovepress.com/designing-biologic-selectivity-for-inflammatory-bowel-disease-ndash-ro-peer-reviewed-article-DDDT

Niklas Krupka, Daniel C Baumgart Division of Gastroenterology and Hepatology, Department of Medicine, Charité Medical School, Humboldt-University of Berlin, Berlin, Germany Abstract: Crohn’s disease and ulcerative colitis are two chronic inflammatory bowel conditions. Current approved biologic therapies are limited to blocking tumor necrosis factor alpha. Unfortunately, some patients are primary nonresponders, experiencing a loss of response, intolerance, or side effects. This defines an unmet need for novel therapeutic strategies. The rapid recruitment and inappropriate retention of leukocytes is a hallmark of chronic inflammation and a potentially promising therapeutic target. Here we discuss the clinical trial results of vedolizumab (anti-α4β7, LDP-02, MLN-02, and MLN0002) and its impact on future management of inflammatory bowel disease. Keywords: ulcerative colitis, Crohn’s disease, vedolizumab, MLN0002, MLN-02, LDP-02, anti-α4β7